Edwards Lifesciences(DE:EWL)
€94.38+1.70 (+1.83%)
DE:EWL
Edwards Lifesciences stock forecast
€94.38
At close:+1.70 (+1.83%)
Edwards Lifesciences (EWL) Stock Forecast & Price Target
3 Followers
EWL Analyst Ratings
Strong Buy
20Buy3Hold0Sell
Based on 23 analysts giving stock ratings to Edwards Lifesciences in the past 3 months
EWL Stock 12 Month Forecast
Average Price Target
€102.52▲(8.62% Upside)Based on 23 Wall Street analysts offering 12 month price targets for Edwards Lifesciences in the last 3 months. The average price target is EUR 102.52 with a high forecast of EUR 111.92 and a low forecast of EUR 86.85. The average price target represents a 8.62% change from the last price of EUR 94.38.
Past 12 Months12 Month ForecastJan2026Oct2026
High€111.92
Average€102.52
Low€86.85
Highest Price TargetHighest€111.92Average Price Target€102.52Lowest Price TargetLowest€86.85
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
 Jaret SeibergNot Ranked | TD Cowen | €104.76→€108.34 | buy | 14.79%Upside | Assigned | 11/11/26 | ||
| Travis Steed | Bank of America Securities | ― | buy | ― | Reiterated | 11/09/26 | ||
| Christopher Pasquale | Barclays | €98.49→€107.44 | buy | 13.84%Upside | Reiterated | 11/05/26 | ||
| William Plovanic | Canaccord Genuity | €76.10→€86.85 | hold | -7.98%Downside | Reiterated | 11/05/26 | ||
| Nico Chen | DBS | €111.92 | buy | 18.58%Upside | Reiterated | 11/05/26 | ||
| Joanne Wuensch | Citi | €98.49→€104.76 | buy | 10.99%Upside | Reiterated | 11/05/26 | ||
| Larry Biegelsen | Wells Fargo | €89.53→€101.17 | buy | 7.20%Upside | Assigned | 11/05/26 | ||
| Patrick Wood | UBS | €98.49→€105.65 | buy | 11.94%Upside | Assigned | 11/05/26 | ||
| Lee Hambright | Bernstein | €88.64→€94.91 | hold | 0.56%Upside | Reiterated | 11/05/26 | ||
| Adam Maeder | Piper Sandler | €90.43→€102.97 | buy | 9.10%Upside | Reiterated | 11/05/26 | ||
| Kendall Au | RBC Capital | €98.49→€102.97 | buy | 9.10%Upside | Reiterated | 11/05/26 | ||
| Robbie Marcus | J.P. Morgan | €94.01→€107.44 | buy | 13.84%Upside | Reiterated | 11/05/26 | ||
| Rick Wise | Stifel Nicolaus | €98.49→€107.44 | buy | 13.84%Upside | Reiterated | 11/05/26 | ||
| David Roman | Goldman Sachs | €98.49→€102.97 | buy | 9.10%Upside | Reiterated | 11/05/26 | ||
| David Rescott | Robert W. Baird | €80.58→€103.86 | buy | 10.05%Upside | Upgraded | 11/05/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Jaret SeibergTD CowenNot Ranked | BuyAssigned€104.76→€108.34 | 11/11/26 | 14.79%Upside | ||
| Travis SteedBank of America Securities | BuyReiterated | 11/09/26 | ― | ||
| Christopher PasqualeBarclays | BuyReiterated€98.49→€107.44 | 11/05/26 | 13.84%Upside | ||
| William PlovanicCanaccord Genuity | HoldReiterated€76.10→€86.85 | 11/05/26 | -7.98%Downside | ||
| Nico ChenDBS | BuyReiterated€111.92 | 11/05/26 | 18.58%Upside | ||
| Joanne WuenschCiti | BuyReiterated€98.49→€104.76 | 11/05/26 | 10.99%Upside | ||
| Larry BiegelsenWells Fargo | BuyAssigned€89.53→€101.17 | 11/05/26 | 7.20%Upside | ||
| Patrick WoodUBS | BuyAssigned€98.49→€105.65 | 11/05/26 | 11.94%Upside | ||
| Lee HambrightBernstein | HoldReiterated€88.64→€94.91 | 11/05/26 | 0.56%Upside | ||
| Adam MaederPiper Sandler | BuyReiterated€90.43→€102.97 | 11/05/26 | 9.10%Upside | ||
| Kendall AuRBC Capital | BuyReiterated€98.49→€102.97 | 11/05/26 | 9.10%Upside | ||
| Robbie MarcusJ.P. Morgan | BuyReiterated€94.01→€107.44 | 11/05/26 | 13.84%Upside | ||
| Rick WiseStifel Nicolaus | BuyReiterated€98.49→€107.44 | 11/05/26 | 13.84%Upside | ||
| David RomanGoldman Sachs | BuyReiterated€98.49→€102.97 | 11/05/26 | 9.10%Upside | ||
| David RescottRobert W. Baird | BuyUpgraded€80.58→€103.86 | 11/05/26 | 10.05%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Edwards Lifesciences
3 Months
Success Rate20/30 ratings generated profit
67%
Average Return
+2.00%
Copying Adam Maeder's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +2.00% per trade.
1 Year
Success Rate11/11 ratings generated profit
100%
Average Return
+16.88%
Copying Brandon Vazquez's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +16.88% per trade.
2 Years
Success Rate11/11 ratings generated profit
100%
Average Return
+21.73%
Copying Brandon Vazquez's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.73% per trade.
EWL Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 39 | 34 | 25 | 17 | 37 |
| Hold | 6 | 7 | 5 | 1 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 45 | 41 | 30 | 18 | 40 |
In the current month, EWL has received 37 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. EWL average Analyst price target in the past 3 months is 102.52.
EWL Financial Forecast
High€0.64
Consensus€0.59
Low€0.57
EWL Earnings Forecast
Next quarter’s earnings estimate for EWL is EUR 0.59 with a range of EUR 0.57 to EUR 0.64. The previous quarter’s EPS was EUR 0.72. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€1.55B
Consensus€1.53B
Low€1.52B
EWL Sales Forecast
Next quarter’s sales forecast for EWL is EUR 1.53B with a range of EUR 1.52B to EUR 1.55B. The previous quarter’s sales results were EUR 1.54B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
EWL Stock Forecast FAQ
What is DE:EWL’s average 12-month price target, according to analysts?
Based on analyst ratings, Edwards Lifesciences’s 12-month average price target is €102.52.
What is DE:EWL’s upside potential, based on the analysts’ average price target?
Edwards Lifesciences has 8.62% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Edwards Lifesciences a Buy, Sell or Hold?
Edwards Lifesciences has a consensus rating of Strong Buy, which is based on 20 buy ratings, 3 hold ratings and 0 sell ratings.
What is Edwards Lifesciences’s share price target?
The average share price target for Edwards Lifesciences is €102.52. This is based on 23 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €111.92, and the lowest forecast is €86.85. The average share price target represents a 8.62% increase from the current price of €94.38.
What do analysts say about Edwards Lifesciences?
Edwards Lifesciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Street analysts.
How can I buy shares of Edwards Lifesciences?
To buy shares of DE:EWL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
